REDOX BASED PRODRUGS FOR SOLID TUMOR TARGETTING

用于实体瘤靶向的基于氧化还原的前药

• 批准号: 2725091
• 负责人: PRASHANT J CHIKHALE
• 金额: $ 10.6万
• 依托单位: UNIVERSITY OF MARYLAND BALTIMORE
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-05-01 至 2002-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2725091
• 关键词: acivicin; antineoplastics; blood brain barrier; brain metabolism; chemical property; chemical stability; conformation; drug design /synthesis /production; drug metabolism; drug screening /evaluation; hydropathy; neoplasm /cancer chemotherapy; neoplasm /cancer pharmacology; neurotoxicology; oxidation reduction reaction; pharmacokinetics; physical property; prodrugs; tissue /cell culture

项目成果

Drug delivery systems for brain tumor therapy.

用于脑肿瘤治疗的药物输送系统。

• DOI: 10.2174/1381612043384916
• 发表时间: 2004
• 期刊: Current pharmaceutical design
• 影响因子: 3.1
• 作者: Rautioa,Jarkko;Chikhale,PrashantJ
• 通讯作者: Chikhale,PrashantJ

Stability of bioreductive drug delivery systems containing melphalan is influenced by conformational constraint and electronic properties of substituents.

含有美法仑的生物还原药物递送系统的稳定性受到取代基的构象约束和电子特性的影响。

• DOI: 10.1016/s0960-894x(00)00496-0
• 发表时间: 2000
• 期刊: Bioorganic & medicinal chemistry letters
• 影响因子: 2.7
• 作者: Weerapreeyakul,N;Hollenbeck,RG;Chikhale,PJ
• 通讯作者: Chikhale,PJ